. 2006 Dec;2(4):417–434. doi: 10.2147/tcrm.2006.2.4.417

Table 3.

Mean ± SD pharmacokinetic parameters of moxifloxacin in healthy adult volunteers

Reference	n	Regimen	C_max (mg/L)	T_max (h)	t 1/2 (h)	CL/F (L/h)	CL_R (L/h)	F_e (%)
(1)	11	400 mg PO × 1	2.53 ± 1.31	1.0^a	14.6 ± 1.18	13.7 ± 1.16	3.17 ± 1.12	23.2 ± 2.7
(2)	12	400 mg PO qd
		dose 1	3.10 ± 0.60^b	1.67 ± 0.96	10.6^a,^b	11.6 ± 2.1	———	———
		dose 7	3.98 ± 1.10^b	1.59 ± 0.79	14.9^a,^b	10.4 ± 2.0	———	———
(3)	12	400 mg PO × 1	2.50 ± 1.29	2 .0^a	15.6 ± 1.15	11.6 ± 1.21	2.58 ± 1.25	19.3 ± 2.8
(4)	8	400 mg PO × 1	4.38 ± 1.4	0.77^a	14.9 ± 1.5	9.2 ± 1.4	2.3 ± 1.3	24.2 ± 1.4
(5)	16	400 mg PO × 1	2.8 (31.7%)^c	1.0^a	11.5 (12.8%)^c	———	———	———
(6)	8^d	200 mg PO × 1	1.31	1.28	13.16	10.61	2.25	19.63
	8^e		1.55	0.97	12.42	10.38^b	1.84	16.60
	8^f		1.92	1.50	11.47	8.05^b	1.74	20.55
(7)	8	100 mg PO bid × 5 days
		day 1	0.63 ± 1.47	2.0^a	9.39 ± 1.08	13.1 ± 1.25	2.54 ± 1.28	15.8 ± 1.21
		day 5	0.90 ± 1.28	1.5^a	13.7 ± 1.20	13.8 ± 1.22	3.32 ± 1.31	24.0 ± 1.24
	8	200 mg PO bid × 5 days
		day 1	1.16 ± 1.96	1.5^a	10.4 ± 1.26	14.0 ± 1.33	3.24 ± 1.36	18.2 ± 1.24
		day 5	1.96 ± 1.23	1.3^a	15.0 ± 1.18	13.1 ± 1.26	3.08 ± 1.29	23.5 ± 1.34
	7	400 mg PO qd × 5 days
		day 1	3.10 ± 1.34	0.5^a	9.6 ± 1.12	12.9 ± 1.12	2.33 ± 1.27	14.7 ± 1.25
		day 5	3.24 ± 1.19	1.5^a	15.1 ± 1.05	11.8 ± 1.22	2.51 ± 1.14	21.3 ± 1.19
	7	600 mg PO qd × 10 days
		day 1	4.21 ± 1.18	1.0^a	9.11 ± 1.16	11.9 ± 1.26	3.30 ± 1.62	23.0 ± 1.46
		day 10	5.67 ± 1.19	1.5^a	13.7 ± 1.06	10.0 ± 1.23	2.41 ± 1.15	24.2 ± 1.18
(8)	12	400mg PO × 1	4.34 ± 1.61	1.02 ± 0.72	9.15 ± 1.62	———	30.5 ± 6.18^g	19.9 ± 4.55
(9)	7	400 mg PO × 1	4.98 ± 1.01	1.0 ± 0.91	8.32 ± 1.70	147.8^h	22.3^h	15.10 ± 3.61
		400 mg IV × 1	5.09 ± 1.11	———	8.17 ± 1.58	151.5h	23.0^h	15.2 ± 3.40
(10)	10	100 mg PO × 1	1.15	0.86	13.5	———	———	24.4
		100 mg IV × 1	1.34	———	12.7	———	———	25.3
(11)	7ⁱ	400 mg PO qd
	3^j	× 10 days
		day 1	3.36 (21.5%)^c	1.49 (62.2%)^c	9.30 (12.1%)^c	———	———	———
		day 10	4.52 (12.2%)c	1.24 (48.0%)c	11.95 (10.8%)c	———	———	———
		400 mg PO × 1	2.53 ± 1.31	1.0^a	14.6 ± 1.18	13.7 ± 1.16	3.17 ± 1.12	23.2 ± 2.7
(12)	6	50 mg PO × 1	0.29 ± 1.25	1.75^a	11.4 ± 1.11	12.9 ± 1.13	2.77 ± 1.22	20.4 ± 1.15
	6	100 mg PO × 1	0.59 ± 1.21	2.0^a	12.2 ± 1.11	11.8 ± 1.21	2.38 ± 1.25	18.9 ± 1.34
	6	200 mg PO × 1	1.16 ± 1.35	2.50^a	14.0 ± 1.14	13.0 ± 1.20	2.64 ± 1.25	19.8 ± 1.16
	7	400 mg PO × 1	2.50 ± 1.31	1.5^a	13.1 ± 1.06	14.9 ± 1.18	3.03 ± 1.17	20.1 ± 1.20
	7	600 mg PO × 1	3.19 ± 1.19	2.5^a	12.5 ± 1.14	15.0 ± 1.11	2.67 ± 1.10	17.5 ± 1.16
	7	800 mg PO × 1	4.73 ± 1.16	3.0^a	12.3 ± 1.13	13.4 ± 1.24	2.50 ± 1.28	18.7 ± 1.25

Abbreviations: bid, twice daily; C_max, peak serum concentration; CL/F, total body clearance; CL_R, renal clearance; F_e, fractional elimination in urine as unchanged parent compound; IV, intravenous; T_max, time to C_max; t^½, terminal disposition half-life; PO, oral; qd, once daily.

Notes: Median;

Links parameters that are significantly different (p ≤ 0.05);

% coefficient of variation;

Young males (mean age, 32);

Older males (mean age, 74);

Older females (mean age, 74);

mL/min/1.73m²;

Mean values in mL/min;

ⁱ

Male;

Female.

References:1, Stass et al 2004; 2, Burkhardt et al 2002; 3, Stass and Kubitza 1999; 4, Stass et al 2002; 5, Lettieri et al 2001; 6, Sullivan et al 2001; 7, Stass et al 2001; 8, Lubasch et al 2000; 9,Wise et al 1999; 10, Ballow et al 1999; 11, Sullivan et al 1999; 12, Stass et al 1998.